Under the agreement, Amsino will direct worldwide sales of CytoCore’s SoftPAP cervical cell collector kits through its channel of distribution partners. Where applicable, such as China, Amsino will sell CytoCore’s products directly to laboratories, and physicians and other medical providers through its direct sales force.
Pursuant to the terms of the agreement, Amsino will be responsible for transportation and warehousing logistics, order management, customer service, quality assurance and bill collection.
According to CytoCore, the SoftPAP cervical cell collector kit offers quicker, more accurate specimen collection with minimal possibility of user error. It is designed to consistently sample the entire cervix in a single-step using an inflatable balloon collector. The results of the clinical trial, conducted by CytoCore and announced in October 2008, demonstrated that sampling in this manner improves the sensitivity and specificity of the diagnosis.
Robert McCullough Jr, CEO of CytoCore, said: “This agreement with Amsino will significantly enhance SoftPAP’s presence in the market and help generate increased sales. We look forward to working with Amsino to explore opportunities to leverage additional areas of their expertise with regard to CytoCore’s present and future product lines.”